persist, and there is no international regulation to cover this particular type of research. 6 Unfortunately, even a cursory review of the Recommendation exposes the fact that it contains little in the way of original contribution to biomedical research regulation; it reiterates well worn general principles, albeit in the context of biobanks (and population biobanks). 7 However, the excised human tissue storage/research context throws up unique regulatory issues and opportunities, making the Council's status quo approach is somewhat disappointing. A few observations should serve to illustrate the narrowness of its approach. Thus, after first briefly review the Recommendation's philosophical foundation and substantive content, I will address some key issues of particular relevance to biobanks, namely (1) consent, (2) commercialisation, (3) custodianship, and (4) collapse.
Analysis

I. Perspective and provisions of the recommendation
That the human rights perspective (founded on the values of autonomy and equality) informed the Council's effort, and that the Recommendation is intended to be a human rights protecting instrument is obvious from the Explanatory Memorandum:
… If [human biological material] were not utilised and research had to be undertaken relying only on prospective collection of biological materials specifically for each project, it would mean … comparable research results would not be available for … years. … The purpose of this recommendation is to set out and safeguard fundamental rights of individuals whose biological materials are used in biomedical research, while recognising the importance of freedom of research. Steering Committee on Bioethics, supra, note 6, at 2-3.
It is equally obvious from the first provisions of the Recommendation itself, which commences by enunciating some general principles applicable to the full range human tissue research and human tissue banking. In particular, the Preamble states that:
the interests and welfare of tissue donors shall prevail over others' interests; appropriate and transparent governance of stored human tissue is important; people must be freed to accept or refuse to contribute to biomedical research; a paramount concern should be protection of the human being; and measures must be taken to safeguard human dignity and individual rights.
Article 1 then directs member states to protect the dignity, identity, private life, integrity, and other fundamental freedoms, without discrimination, of all human beings with regard to research.
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Article 2 articulates the scope of the Recommendation, stating that it applies to "biological material of human origin". It specifies that this phrase does not include embryonic or foetal tissue, 10 but does include associated personal data (eg: data derived from biological samples).
11 Unfortunately, it does not go on to define this phrase with any greater particularity; it could include cadavers, organs, tissues (biopsy and surgical specimens), cells (from organs, umbilical cord, bone marrow or gonadic), body fluids (blood, semen, saliva), hair, nails and body waste products (urine, faeces).
12 Article 3 defines "identifiable biological materials" as "identified", "coded" or "linked anonymised", and "non-identifiable biological materials" as "unlinked anonymised". 13 Article 8 states that tissue and data should be "anonymised as far as appropriate to the research concerned", and that any use of "identified", "coded" or "linked anonymised" tissue/data should be justified. Reflecting the autonomy/equality based human rights foundation of the Recommendation, Articles 5 and 6 state that risks to participants and their families, particularly regarding private life and discrimination, should be "minimised", and risks should not be disproportionate to the potential benefit of the research. Article 7 states that biological materials should not, as such, give rise to financial gain. This is an oft flogged provision intended to keep tissue originators from receiving financial rewards in exchange for their tissue, and is widely (though certainly not universally) deemed necessary to protect human dignity and avoid undue influence and instrumentalisation of the person. Article 9 stipulates that the Recommendation does not limit the ability of member states to grant wider protections. The remainder of the Recommendation addresses more specifically the mechanics of procuring human tissue (with an unsurprising emphasis on consent), collecting human tissue in biobanks, and subsequent use of human tissue in research projects. These matters are considered in greater detail below within the context of the four issues of particular concern to biobank operations.
II.
The recommendation's management of the four "Cs"
Consent
The Recommendation deals with individual consent at some length. As a preliminary matter, it states that, whether seeking tissue from adults, minors or cadavers, the information provided to the person authorised to give consent, and the consent obtained should be as specific as possible with regard to any foreseen research. 14 Further, whenever possible, consent should be obtained before tissue is removed. 15 Research undertaken on the tissue should fall within the scope of the consent given, even where the tissue is unlinked anonymised. 16 Where a research project falls outside the consent, "reasonable efforts" should be made to re-contact the person and obtain consent. 17 If this is not possible, the tissue/data can be used subject to an "independent evaluation" (by an independent ethics review board?) concluding that the project fulfils certain conditions, namely that: 18 a) the research addresses an important scientific interest; b) the research's aims could not reasonably be achieved using tissue for which consent can be obtained; and c) there is no evidence that the person expressly opposed such research.
These criteria throw up some obvious questions with which national legislators or the independent review body will have to grapple: Is the scientific interest ever not important and from whose perspective is that determination made? What is the balance of convenience surrounding re-contact? How would the collection custodian know what a participant opposes; would it be contained on the consent form? Interestingly, the Recommendation also states that consent can contain restrictions on the use of the tissue/data, and it can be altered or withdrawn at any time, and such must not lead to discrimination against the participant.
19 In the event of withdrawal, the tissue must be destroyed or rendered "unlinked anonymised".
20
This means that the tissue, alone or in combination with associated data, does not allow, with "reasonable efforts", the identification of the persons concerned.
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The Recommendation gives no indication as to what might constitute "reasonable efforts". The practical implications of this position would seem to be: increased complexity of consent forms; increased administrative duties related to policing a system of different categories/classes of participants and potentially shifting participants from one category to another; increased expenses and potentially prohibitive budgetary demands; and increased likelihood of negative knock-on effects for specific research projects.
Consent is never easy to get right, and it is manifestly more difficult in the biobank context, which is unique in that biobanks are: 22 collective (relying on mass participation); inclusive (recruiting healthy people and most effective with children recruits); prospective (ideally enduring beyond the life of original participants); and purposively indeterminate (impossible for clinicians, custodians, or current researchers to inform participants of future research ends and therefore of potential risks and benefits).
This reality sits uneasily with our over-emphasis on specific and individual consent and its use as the panacea for promoting human dignity. Even the few observations made above demonstrate this uneasiness, and suggest that the multiple provisions addressing consent in the Recommendation are sure to prompt interesting responses, particularly from custodians of existing biobanks which do not offer participants such a range of options. Parenthetically, as an alternative to consent but without having to abandon all of the mechanisms erected, it seems more appropriate in the biobank context for the custodian to obtain the "agreement" of the subject to participate in the biobank (eg: donate tissue and information), and "permission" for the excised tissue to participate in future unknown research within reasonably articulated parameters. This may be semantic, but it has the benefit of not stretching our understanding of valid informed consent out of all proportion for the purpose of pursuing biobanks. In addition, assuming the custodian obtains agreement and permission, and drawing on solidarity, 23 one might question the value of permitting participants to withdraw from biobanks completely.
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Commercialisation
The Recommendation employs the rhetoric of solidarity as the basis for tissue donation. 25 It then reiterates the standard admonition that biological material should not, as such, give rise to financial gain. 26 However, it is deafeningly silent on all other aspects commercialisation and financial gain. For example, it offers no guidance concerning the economics of running a biobank (ie: allowable fees for making the resource available to private researchers), and, more significantly, it is mute as to the duties of the profit-seeking private research entities who are expected to use collections. Aside from a bland statement against discrimination and stigmatisation, there is nothing about their duty to conduct and to avoid certain types of research, or to contribute to basic knowledge and public health through biobank-facilitated research. This is a troubling lacunae for at least two reasons. First, biobank usage is now and is expected in future to be driven largely by economic interests. 27 Second, it should by now be clear to regulators that publics have concerns around the role and conduct of profit-seeking entities in human subject research and public healthcare agenda-setting. 28 Some guidance around biobank user duties would go far in promoting trust in tissue originators and the public of biobanks, biobank custodians and biobank utilisers; trust being an essential component of the success of biobanks and medical research more generally.
29 I would suggest that such guidance would go farther than the "right to withdraw" in promoting this trust. Additionally, if the Council of Europe was truly interested in advancing solidarity and more effectively promoting trust, it would have articulated some concrete duty to benefit share whenever this resource was used, and offered some specific guidance or principles or model example with respect to benefit sharing.
Custodianship
The Recommendation states that "appropriate and transparent" governance of human tissue is essential, 30 and it goes on to give some content to this claim by suggesting that governance structures and instruments should: These conditions, and compliance with transparency and accountability as the governing principles of biobank management, are all very useful and sensible, but I would suggest that they are not enough. The Recommendation offers no suggestion as to what constitutes an appropriate consequence for serious breach of these provisions. Without sanctions, all of these very useful "rules" may amount to very little. Further, it pays little attention to the duties of biobank custodians to realise a significant contribution to "saving lives and improving their quality", a widely claimed aim for biobanks. 38 For example, there is nothing directing custodians to proactively steer the usage of the biobank toward broadly beneficial projects that will enhance (public) healthcare and thereby maximise their contribution to worthy, publicly endorsed ends. 39 Usage is left in the hands of the (largely private, profit-seeking) entities who choose to submit research proposals to the custodian. At least there is some ethical oversight envisioned, but this does little to ensure that public (and international), as opposed to purely commercial, ends are pursued.
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Collapse
A perceived strength of biobanks is their promise of durability and growth (which fuels anticipation that future projects will be increasingly benefited). However, experience has already demonstrated that biobanks can fail. 41 What is the appropriate regulatory response to failure of a biobank? The Recommendation does not address this, saying only that "procedures should be developed for the … closure of a population biobank". 42 An instrument directed at human tissue use and banking, with their unique possibility of unanticipated collapse, should surely be 36 expected to address this issue more squarely by articulating some baseline principled rules with respect to winding down (and the transfer or destruction of the tissue which made the resource so valuable in the first place).
Conclusion
Given the obvious and direct applicability of other instruments to this field, one wonders about the potential impact of the Recommendation. However, having decided to act, the Council of Europe should have taken more direct notice of the sui generis nature of biobanks and their special possibilities and pitfalls, which places their regulation in a unique position to draw on and provide a strong vehicle for the realisation of important values like solidarity. I understand that the Recommendation is an international instrument intended for uptake by differing political/legal cultures, and, as such, it is possible that the drafters attempted to keep it reasonably open (non-specific). Indeed, they may question the wisdom of offering examples, models and suggested sanctions (as has been suggested above). However, because this is an international instrument which is really only intended to serve as a model for regulation, I suggest that offering examples and models is indubitably appropriate. More specific and binding domestic laws will likely only be loosely based on it (if at all) and will likely cherry pick from the provisions deemed most appropriate. Offering the most comprehensive example of regulation might make the Recommendation more useful to drafters. Considering that the aim of the Convention on Human Rights and Biomedicine (ETS No. 164, hereinafter referred to as "the Convention") and of its Additional Protocol concerning biomedical research (CETS No. 195), as defined in Article 1 of both instruments, is to protect the dignity and identity of all human beings and guarantee everyone, without discrimination, respect for their integrity and other rights and fundamental freedoms with regard to the application of biology and medicine;
COUNCIL OF EUROPE COMMITTEE OF MINISTERS
Considering that progress in medical and biological sciences, in particular advances obtained through biomedical research, including research using biological materials donated in a spirit of solidarity, contributes to saving lives and improving their quality;
Conscious of the fact that the advancement of biomedical science and practice is dependent on knowledge and discovery which necessitates research on human beings and research involving the use of biological materials of human origin;
Stressing that such research is often transdisciplinary and international;
Taking into account the current and planned development of collections and banks of biological materials at national level;
Taking into account national and international professional standards in the area of biomedical research and the previous work of the Committee of Ministers and the Parliamentary Assembly of the Council of Europe in this field;
Convinced that biomedical research that is contrary to human dignity and human rights should never be carried out;
Stressing that the paramount concern should be the protection of the human being whose biological materials are removed, stored or used for research;
Recalling that research on biological materials should be carried out freely subject to the provisions of this recommendation and the other legal provisions ensuring the protection of the human being;
Emphasising that the interests and welfare of the human being whose biological materials are used in research shall prevail over the sole interest of society or science;
Affirming that particular protection shall be given to human beings who may be vulnerable in the context of research;
Recognising that every person has the right to accept or refuse to contribute to biomedical research and that no one should be forced to contribute to it; Stressing the importance of appropriate and transparent governance of biological materials stored for research purposes;
Stressing that population biobanks developed on the basis of donations of biological materials made in a spirit of solidarity should not be monopolised by small groups of researchers;
Resolving to take such measures as are necessary to safeguard human dignity and the rights and fundamental freedoms of the individual with regard to biomedical research on biological materials of human origin, Recommends that the governments of member states adapt their laws and practices to the guidelines contained in appendix to this recommendation and promote the establishment of practice guidelines to ensure compliance with the provisions contained in this appendix; Member states should protect the dignity and identity of all human beings and guarantee everyone, without discrimination, respect for their integrity, right to private life and other rights and fundamental freedoms with regard to any research governed by this recommendation.
Article 2 -Scope
1. This recommendation applies to the full range of research activities in the health field involving the removal of biological materials of human origin to be stored for research use.
2. It also applies to the full range of research activities in the health field involving the use of biological materials of human origin that were removed for a purpose other than that mentioned in the previous paragraph; this includes material removed for a previous research project. 3 . This recommendation does not apply to embryonic and foetal tissues.
4. The use of biological material of human origin may be accompanied by the use of associated personal data.
Article 3 -Identifiability of biological materials
Biological materials referred to in Article 2 may be identifiable or non-identifiable:
i. Identifiable biological materials are those biological materials which, alone or in combination with associated data, allow the identification of the persons concerned either directly or through the use of a code.
In the latter case, the user of the biological materials may either:
a. have access to the code: the materials are hereafter referred to as "coded materials"; or b. not have access to the code, which is under the control of a third party: the material are hereafter referred to as "linked anonymised materials".
ii. Non-identifiable biological materials, hereafter referred to as "unlinked anonymised materials", are those biological materials which, alone or in combination with associated data, do not allow, with reasonable efforts, the identification of the persons concerned.
CHAPTER II General provisions Article 4 -Codes of good practice
Member states should promote the establishment of codes of good practice to ensure compliance with the provisions of this recommendation.
Article 5 -Risks and benefits
1. The risks for the persons concerned and, where appropriate, for their family, related to research activities, in particular the risks to private life, should be minimised, taking into account the nature of the research activity. Furthermore, those risks should not be disproportionate to the potential benefit of the research activities.
2. Possible risks for the individuals in the same group as the person concerned should also be taken into consideration in this context.
Article 6 -Non-discrimination
Appropriate measures should be taken, in the full range of research activities, to avoid discrimination against, or stigmatisation of, a person, family or group.
Article 7 -Prohibition of financial gain
Biological materials should not, as such, give rise to financial gain.
Article 8 -Justification of identifiability
1. Biological materials and associated data should be anonymised as far as appropriate to the research activities concerned.
2. Any use of biological materials and associated data in an identified, coded, or linked anonymised form should be justified by the researcher.
Article 9 -Wider protection
None of the provisions of this recommendation should be interpreted as limiting or otherwise affecting the possibility for a member state to grant a wider measure of protection than is stipulated in this recommendation.
2. The purpose(s) of a collection should be specified. The principles of transparency and accountability should govern its management, including access to and use and transfer of its biological materials and disclosure of information.
3. Each sample of biological material in the collection should be appropriately documented, including information on any relevant consent or authorisation.
4. Clear conditions governing access to, and use of, the samples should be established.
5. Quality assurance measures should be in place, including conditions to ensure security and confidentiality during storage and handling of the biological materials.
Article 15 -Right to change the scope of, or to withdraw, consent or authorisation 1. When a person has provided consent to storage of identifiable biological materials for research purposes, the person should retain the right to withdraw or alter the scope of that consent. The withdrawal or alteration of consent should not lead to any form of discrimination against the person concerned, in particular regarding the right to medical care.
When identifiable biological materials are stored for research purposes only, the person who has withdrawn consent should have the right to have, in the manner foreseen by national law, the materials either destroyed or rendered unlinked anonymised.
2. Where authorisation has been given on behalf of a person not able to consent, the representative, authority, person or body provided for by law should have the rights referred to in paragraph 1 above.
3. Where a person on whose behalf authorisation has been given attains the capacity to give consent, that person should have the rights referred to in paragraph 1 above.
Article 16 -Transborder flows
Biological materials and associated personal data should only be transferred to another state if that state ensures an adequate level of protection.
CHAPTER V Population biobanks
Article 17 -Scope of chapter V 1. A population biobank is a collection of biological materials that has the following characteristics:
i. the collection has a population basis;
ii. it is established, or has been converted, to supply biological materials or data derived therefrom for multiple future research projects; iii. it contains biological materials and associated personal data, which may include or be linked to genealogical, medical and lifestyle data and which may be regularly updated; iv. it receives and supplies materials in an organised manner.
2. Population biobanks should meet the requirements set out in this chapter in addition to those of chapter IV.
